QUADRUPLEX-BASED DETECTION OF A TARGET NUCLEIC ACID
20230183784 · 2023-06-15
Inventors
Cpc classification
C12Q1/6818
CHEMISTRY; METALLURGY
C12Q2525/30
CHEMISTRY; METALLURGY
C12Q1/6883
CHEMISTRY; METALLURGY
C12Q2525/30
CHEMISTRY; METALLURGY
International classification
Abstract
Disclosed herein are oligonucleotides and methods for detecting a target nucleic acid, as well as methods of diagnosing a subject with a disease or a disorder by detecting a target nucleic acid using the oligonucleotides and methods disclosed herein. The oligonucleotides include a quadruplex-forming sequence. Prior to binding the target nucleic acid, the quadruplex-forming sequence is in a non-quadruplex conformation. Upon binding the target nucleic acid, the sequence transforms to the quadruplex conformation, which can be detected, for example, using optical methods. The methods are based on thermodynamic properties and do not require the use of enzymes. The methods can be used to diagnose a subject with a disease or a disorder, prognose the outcome of a disease or disorder, or predict the development of a future disease or disorder.
Claims
1. A method for detecting a target nucleic acid, the method comprising: obtaining a sample, the sample comprising the target nucleic acid having a target sequence; providing an oligonucleotide, the oligonucleotide comprising a first nucleotide sequence comprising a quadruplex-forming sequence and a second nucleotide sequence operably linked to the first nucleotide sequence, the second nucleotide sequence being sufficiently complementary to the target sequence to hybridize therewith; binding the target sequence to the second nucleotide sequence, thereby inducing the quadruplex-forming sequence to take a quadruplex conformation; and detecting the oligonucleotide in the quadruplex conformation.
2. The method of claim 1, wherein the quadruplex-forming sequence comprises the formula G.sub.3+N.sub.1-7G.sub.3+N.sub.1-7G.sub.3+X.sub.1-7G.sub.0-3, the G content of the quadruplex-forming sequence is equal to or greater than 70%, N is any nucleotide, and X is a labeling compound or any nucleotide.
3. The method of claim 1, wherein the quadruplex-forming sequence comprises GGGCGGGCGGG(2AP)GGG (SEQ ID NO: 1).
4. The method of claim 1, further comprising forming a hairpin conformation with the oligonucleotide prior to binding the target sequence, wherein forming a hairpin conformation comprises hybridizing a stem sequence of the second nucleotide to the quadruplex-forming sequence of the first nucleotide sequence.
5. The method of claim 4, further comprising stabilizing the hairpin configuration with cesium ions, magnesium ions, or both.
6. The method of claim 4, wherein binding the target sequence to the second nucleotide sequence comprises first binding the target sequence to a toehold sequence that is operably linked to the stem sequence while the oligonucleotide is in the hairpin conformation.
7. The method of claim 4, wherein binding the target sequence to the second nucleotide sequence further comprises binding the target sequence to the stem sequence while the quadruplex-forming sequence dissociates from the stem sequence.
8. The method of claim 4, wherein the stem sequence comprises the formula C.sub.3+N.sub.1-7 and N is any nucleotide.
9. (canceled)
10. The method of claim 4, further comprising heating the sample, thereby inducing the oligonucleotide to revert from the quadruplex conformation to the hairpin conformation.
11. The method of claim 1, further comprising stabilizing the quadruplex conformation with potassium ions.
12. (canceled)
13. (canceled)
14. The method of claim 1, wherein detecting the oligonucleotide in the quadruplex conformation further comprises registering a change in an optically detectable property.
15. (canceled)
16. (canceled)
17. The method of claim 1, wherein the method is performed without enzymes.
18. The method of claim 1, further comprising quantifying the target nucleic acid.
19. An oligonucleotide for use in binding a target nucleic acid in a non-enzymatic nucleic acid detection assay, the oligonucleotide comprising: a first nucleotide sequence comprising a quadruplex-forming sequence; and a second nucleotide sequence operably linked to the first nucleotide sequence; wherein the quadruplex-forming sequence comprises the formula G.sub.3+N.sub.1-7G.sub.3+N.sub.1-7G.sub.3+X.sub.1-7G.sub.0-3, the G content of the quadruplex-forming sequence is equal to or greater than 70%, N is any nucleotide, and X is a detectable labeling compound or any nucleotide; wherein the second nucleotide sequence comprises a stem sequence and a toehold sequence, the stem sequence being sufficiently complementary to a portion of the quadruplex-forming sequence to hybridize therewith and sufficiently complementary to a portion of the target nucleic acid to hybridize therewith, the toehold sequence being sufficiently complementary to the target nucleic acid to hybridize therewith; and wherein the stem sequence comprises the formula C.sub.3+N.sub.1-7.
20. (canceled)
21. (canceled)
22. The oligonucleotide of claim 19, wherein the oligonucleotide takes a hairpin conformation under a first set of conditions, and wherein the first nucleotide sequence of the oligonucleotide takes a quadruplex-conformation under a second set of conditions.
23. The oligonucleotide of claim 22, wherein the first set of conditions comprises less potassium in the surrounding environment than the second set of conditions.
24. The oligonucleotide of claim 22, wherein the first set of conditions comprises more cesium in the surrounding environment than the second set of conditions.
25. The oligonucleotide of claim 19, wherein the quadruplex-forming sequence comprises at least 70% sequence identity to GGGCGGGCGGG(2AP)GGG (SEQ ID NO: 1).
26. The oligonucleotide of claim 19, wherein the stem sequence comprises at least 70% sequence identity to CCCGC (SEQ ID NO: 2).
27. A method of diagnosing a subject with a disease or a disorder, making a prognosis of a disease or disorder, or predicting the development of a future disease or disorder, by detecting a target nucleic acid, the method comprising: obtaining a bodily sample from the subject, extracting nucleic acids from the bodily sample, contacting the nucleic acids from the bodily sample with an oligonucleotide, the oligonucleotide comprising a first nucleotide sequence comprising a quadruplex-forming sequence and a second nucleotide sequence operably linked to the first nucleotide sequence, the second nucleotide sequence being sufficiently complementary to a target nucleic acid sequence to hybridize therewith; if the target nucleic acid is present within the nucleic acids from the bodily sample, binding the target nucleic acid sequence to the second nucleotide sequence, thereby inducing the oligonucleotide to take a quadruplex conformation; detecting the oligonucleotide in the quadruplex conformation; and correlating the detection of the quadruplex conformation with a diagnosis of the disease or disorder, a prognosis of the disease or disorder, or the development of the disease or disorder.
28. (canceled)
29. (canceled)
Description
DESCRIPTION OF DRAWINGS
[0013] The device is explained in even greater detail in the following drawings. The drawings are merely exemplary and certain features may be used singularly or in combination with other features. The drawings are not necessarily drawn to scale.
[0014]
[0015]
[0016]
[0017]
[0018]
[0019]
[0020]
[0021]
[0022]
[0023]
[0024]
[0025]
[0026]
DETAILED DESCRIPTION
[0027] The following description of certain examples of the inventive concepts should not be used to limit the scope of the claims. Other examples, features, aspects, embodiments, and advantages will become apparent to those skilled in the art from the following description. As will be realized, the device and/or methods are capable of other different and obvious aspects, all without departing from the spirit of the inventive concepts. Accordingly, the drawings and descriptions should be regarded as illustrative in nature and not restrictive.
[0028] For purposes of this description, certain aspects, advantages, and novel features of the embodiments of this disclosure are described herein. The described methods, systems, and apparatus should not be construed as limiting in any way. Instead, the present disclosure is directed toward all novel and nonobvious features and aspects of the various disclosed aspects, alone and in various combinations and sub-combinations with one another. The disclosed methods, systems, and apparatus are not limited to any specific aspect, feature, or combination thereof, nor do the disclosed methods, systems, and apparatus require that any one or more specific advantages be present or problems be solved.
[0029] Features, integers, characteristics, compounds, chemical moieties, or groups described in conjunction with a particular aspect, embodiment or example of the invention are to be understood to be applicable to any other aspect, embodiment or example described herein unless incompatible therewith. All of the features disclosed in this specification (including any accompanying claims, abstract, and drawings), and/or all of the steps of any method or process so disclosed, may be combined in any combination, except combinations where at least some of such features and/or steps are mutually exclusive. The invention is not restricted to the details of any foregoing aspects. The invention extends to any novel one, or any novel combination, of the features disclosed in this specification (including any accompanying claims, abstract, and drawings), or to any novel one, or any novel combination, of the steps of any method or process so disclosed.
[0030] Terms used throughout this application are to be construed with ordinary and typical meaning to those of ordinary skill in the art. However, Applicant desires that the following terms be given the particular definition as defined below.
[0031] As used in the specification and the appended claims, the singular forms “a,” “an” and “the” include plural referents unless the context clearly dictates otherwise. Ranges may be expressed herein as from “about” one particular value, and/or to “about” another particular value. When such a range is expressed, another aspect includes from the one particular value and/or to the other particular value. Similarly, when values are expressed as approximations, by use of the antecedent “about,” it will be understood that the particular value forms another aspect. It will be further understood that the endpoints of each of the ranges are significant both in relation to the other endpoint, and independently of the other endpoint. The terms “about” and “approximately” are defined as being “close to” as understood by one of ordinary skill in the art. In one non-limiting aspect the terms are defined to be within 10%. In another non-limiting aspect, the terms are defined to be within 5%. In still another non-limiting aspect, the terms are defined to be within 1%.
[0032] “Optional” or “optionally” means that the subsequently described event or circumstance may or may not occur, and that the description includes instances where said event or circumstance occurs and instances where it does not.
[0033] As used herein, the term “comprising” is intended to mean that the compositions and methods include the recited elements, but not excluding others. “Consisting essentially of” when used to define compositions and methods, shall mean excluding other elements of any essential significance to the combination. Thus, a composition consisting essentially of the elements as defined herein would not exclude trace contaminants from the isolation and purification method and pharmaceutically acceptable carriers, such as phosphate buffered saline, preservatives, and the like. “Consisting of” shall mean excluding more than trace elements of other ingredients and substantial method steps for administering the compositions of this invention. Aspects defined by each of these transition terms are within the scope of this invention.
[0034] The term “subject” refers to any individual who seeks a diagnosis, a prognosis, or receives a treatment. The subject can be a vertebrate, for example, a mammal. Thus, the subject can be a human or veterinary patient. The term “patient” refers to a subject under the treatment of a clinician, e.g., physician.
[0035] The term “sample from a subject” refers to a tissue (e.g., tissue biopsy), organ, cell (including a cell maintained in culture), cell lysate (or lysate fraction), biomolecule derived from a cell or cellular material (e.g. a polypeptide or nucleic acid), or body fluid from a subject. Non-limiting examples of body fluids include blood, urine, plasma, serum, tears, lymph, bile, cerebrospinal fluid, interstitial fluid, aqueous or vitreous humor, colostrum, sputum, amniotic fluid, saliva, anal and vaginal secretions, perspiration, semen, transudate, exudate, and synovial fluid.
[0036] The terms “prevent,” “preventing,” “prevention,” and grammatical variations thereof as used herein, refer to a method of partially or completely delaying or precluding the onset or recurrence of a disorder or conditions and/or one or more of its attendant symptoms or barring a subject from acquiring or reacquiring a disorder or condition or reducing a subject's risk of acquiring or reacquiring a disorder or condition or one or more of its attendant symptoms.
[0037] The term “nucleic acid” refers to a natural or synthetic molecule comprising a single nucleotide or two or more nucleotides linked by a phosphate group at the 3′ position of one nucleotide to the 5′ end of another nucleotide. The nucleic acid is not limited by length. The nucleic acid can include any deoxyribonucleic acid (DNA) or ribonucleic acid (RNA), DNA-RNA hybrid, single-stranded or double-stranded, sense or antisense, which is capable of hybridization to a complementary nucleic acid by Watson-Crick base-pairing. Nucleic acids can also include nucleotide analogs (e.g., BrdU), and non-phosphodiester internucleoside linkages (e.g., peptide nucleic acid (PNA) or thiodiester linkages). In particular, nucleic acids can include, without limitation, DNA, RNA, cDNA, gDNA, ssDNA, dsDNA or any combination thereof.
[0038] The term “oligonucleotide” refers to a polymeric form of nucleotides of any length, either deoxyribonucleotides or ribonucleotides, or analogs thereof. Oligonucleotides may have any three-dimensional structure, and may perform any function, known or unknown. Oligonucleotide can refer to a sequence of genomic, synthetic, or recombinant origin and may be double-stranded or single-stranded, whether representing the sense or anti-sense strand. The following are non-limiting examples of oligonucleotides: a gene or gene fragment, exons, introns, messenger RNA (mRNA), transfer RNA, ribosomal RNA, ribozymes, cDNA, recombinant polynucleotides, branched polynucleotides, plasmids, vectors, isolated DNA of any sequence, isolated RNA of any sequence, genomic DNA, synthetic DNA, nucleic acid probes, and primers. The oligonucleotide may contain chemical modifications. An oligonucleotide may comprise modified nucleotides, such as methylated nucleotides and nucleotide analogs. If present, modifications to the nucleotide structure may be imparted before or after assembly of the polymer. The sequence of nucleotides may be interrupted by non-nucleotide components. An oligonucleotide may be further modified after polymerization, such as by conjugation with a labeling component. The term also refers to both double- and single-stranded molecules.
[0039] An oligonucleotide is composed of a specific sequence of four nucleotide bases: adenine (A); cytosine (C); guanine (G); thymine (T); and uracil (U) for thymine (T) when the oligonucleotide is RNA. Thus, the term “oligonucleotide sequence” is the alphabetical representation of an oligonucleotide molecule. This alphabetical representation can be input into databases in a computer having a central processing unit and used for bioinformatics applications such as functional genomics and homology searching.
[0040] The term “detectable label,” or “labeling compound” refers to any moiety that can be selectively detected in a screening assay. Examples include without limitation, radiolabels, (e.g., .sup.3H, .sup.14C, .sup.35S, .sup.125I, .sup.131I), affinity tags (e.g. biotin/avidin or streptavidin, binding sites for antibodies, metal binding domains, epitope tags, FLASH binding domains—See U.S. Pat. Nos. 6,451,569; 6,054,271; 6,008,378 and 5,932,474—glutathione or maltose binding domains) fluorescent or luminescent moieties (e.g. fluorescein and derivatives, GFP, rhodamine and derivatives, lanthanides etc.), fluorescent nucleobases (e.g., 2-aminopurine), and enzymatic moieties (e.g. horseradish peroxidase, .beta.-galactosidase, .beta.-lactamase, luciferase, alkaline phosphatase). Such detectable labels can be formed in situ, for example, through use of an unlabeled primary antibody which can be detected by a secondary antibody having an attached detectable label.
[0041] The term “operably linked to” refers to the functional relationship of a nucleic acid with another nucleic acid sequence. Promoters, enhancers, transcriptional and translational stop sites, and other signal sequences are examples of nucleic acid sequences operably linked to other sequences. For example, operable linkage of DNA to a transcriptional control element refers to the physical and functional relationship between the DNA and promoter such that the transcription of such DNA is initiated from the promoter by an RNA polymerase that specifically recognizes, binds to and transcribes the DNA.
[0042] By “probe,” “primer,” is meant a DNA or RNA molecule of defined sequence that can base-pair to a second, complementary DNA or RNA sequence (the “target”). The stability of the resulting hybrid depends upon the extent of the base-pairing that occurs. The extent of base-pairing is affected by parameters such as the degree of complementarity between the probe and target molecules and the degree of stringency of the hybridization conditions.
[0043] By “hybridizes” is meant that an oligonucleotide recognizes and physically interacts (that is, base-pairs) with a substantially complementary nucleic acid under high stringency conditions, and does not substantially base pair with other nucleic acids. The stability of the resulting hybrid depends upon the extent of the base-pairing that occurs. The extent of base-pairing is affected by parameters such as the degree of complementarity between the probe and target molecules and the degree of stringency of the hybridization conditions. The degree of hybridization stringency is affected by parameters such as temperature, salt concentration, and the concentration of organic molecules such as formamide, and is determined by methods known to one skilled in the art.
[0044] When hybridization occurs in an antiparallel configuration between two single-stranded oligonucleotides, those oligonucleotides are described as “complementary”. “Complementarity” is quantifiable in terms of the proportion of bases in opposing strands that are expected to form hydrogen bonding with each other, according to generally accepted base-pairing rules.
[0045] The term “identity” shall be construed to mean the percentage of nucleotide bases or amino acid residues in the candidate sequence that are identical with the bases or residues of a corresponding sequence to which it is compared, after aligning the sequences and introducing gaps, if necessary to achieve the maximum percent identity for the entire sequence, and not considering any conservative substitutions as part of the sequence identity. Neither N- nor C-terminal extensions nor insertions shall be construed as reducing identity or homology. An oligonucleotide or oligonucleotide region that has a certain percentage (for example, 80%, 85%, 90%, or 95%) of “sequence identity” to another sequence means that, when aligned, that percentage of bases are the same in comparing the two sequences. This alignment and the percent homology or sequence identity can be determined using software programs known in the art. In one aspect, default parameters are used for alignment. In one aspect a BLAST program is used with default parameters. In one aspect, BLAST programs BLASTN and BLASTP are used with the following default parameters: Genetic code=standard; filter=none; strand=both; cutoff=60; expect=10; Matrix=BLOSUM62; Descriptions=50 sequences; sort by=HIGH SCORE; Databases=non-redundant, GenBank+EMBL+DDBJ+PDB+GenBank, CDS translations+SwissProtein+SPupdate+PIR.
[0046] Disclosed herein are oligonucleotides and methods for detecting a target nucleic acid. The oligonucleotides include a quadruplex-forming sequence. Prior to binding the target nucleic acid, the quadruplex-forming sequence is in a non-quadruplex conformation. Upon binding the target nucleic acid, the sequence transforms to the quadruplex conformation, which can be detected, for example, using optical methods. The methods are based on thermodynamic properties and do not require the use of enzymes. The methods and oligonucleotides can be used to diagnose a subject with a disease or a disorder, prognose the outcome of a disease or disorder, or predict the development of a future disease or disorder.
[0047] Due to their base pairing properties, nucleic acid sequences can often form specific structures under certain solution conditions. For example, in the presence of certain metal ions (e.g., K.sup.+), short guanine (G)-rich sequences fold into a structure known as a G-quartet or quadruplex. Quadruplexes are high-ordered DNA and RNA structures formed from G-rich sequences that are built around tetrads of hydrogen bonded guanine bases. The synthetic polynucleotides poly(dG) and poly(G) were determined to form four-stranded helical structures, with the G-tetrads stacked on one another, analogous to Watson-Crick base pairs in duplex DNA.
[0048] Quadruplexes are very stable and biophysical studies have shown that they possess natural optical properties (e.g., absorb light at 300 nm) that distinguish them from other secondary structures. When G-rich sequences with the potential to form a quadruplex are incorporated into DNA substrates they are initially in the quenched state. Upon enzymatic activity (i.e., strand cleavage or strand-exchange) the released sequence folds into a quadruplex and becomes visible when monitored by absorption or fluorescence spectroscopy.
[0049] Quadruplexes can be formed from one, two, or four separate strands of DNA (or RNA) and can display a wide variety of topologies, which are in part a consequence of the various possible combinations of strand directions, as well as variations in loop size and sequence. They can be defined in general terms as structures formed by a core of at least two stacked G-tetrads, which are held together by loops arising from the intervening mixed sequence nucleotides that are not usually involved in the tetrads themselves. The combination of the number of stacked G-tetrads, the polarity of the strands, and the location and length of the loops would be expected to lead to a plurality of G quadruplex structures, as is found experimentally (12).
[0050] The oligonucleotides disclosed herein can be used to detect a target nucleic acid in a non-enzymatic nucleic acid detection assay. Referring to
[0051] The second nucleotide sequence 7 of the oligonucleotides disclosed herein includes a stem sequence 9 and a toehold sequence 11. As shown in
[0052] The hairpin conformation can be stabilized by the use of a buffer comprising cesium ions, magnesium ions, or a combination thereof. Altering the concentrations of the ions in the buffer affects the stability of the hairpin structure. In some examples, the hairpin structure is stabilized by a buffer comprising less than 100 milliMolar Mg.sup.2+, including, for example, less than 70 milliMolar Mg.sup.2+, less than 50 milliMolar Mg.sup.2+, less than 30 milliMolar Mg.sup.2+, less than 10 milliMolar Mg.sup.2+, less than 9 milliMolar Mg.sup.2+, less than 8 milliMolar Mg.sup.2+, less than 7 milliMolar Mg.sup.2+, less than 6 milliMolar Mg.sup.2+, less than 5 milliMolar Mg.sup.2+, less than 4 milliMolar Mg.sup.2+, less than 3 milliMolar Mg.sup.2+, less than 2 milliMolar Mg.sup.2+, and less than 1 milliMolar Mg.sup.2+. In some examples, the hairpin structure is stabilized by a buffer comprising less than 200 milliMolar Cs.sup.+, including, for example, less than 150 milliMolar Cs.sup.+, less than 100 milliMolar Cs.sup.+, less than 80 milliMolar Cs.sup.+, less than 70 milliMolar Cs.sup.+, less than 60 milliMolar Cs.sup.+, less than 50 milliMolar Cs.sup.+, less than 40 milliMolar Cs.sup.+, less than 20 milliMolar Cs.sup.+, less than 10 milliMolar Cs.sup.+, less than 5 milliMolar Cs.sup.+, and less than 1 milliMolar Cs.sup.+.
[0053] Upon binding of target sequence 13 to toehold sequence 11 (
[0054] The oligonucleotide 1 takes a hairpin conformation under a first set of conditions. Under a second set of conditions, the quadruplex-forming sequence 5 of the first nucleotide sequence takes a quadruplex-conformation 15 (
[0055] Further, a quadruplex-forming nucleotide sequence may have a detectable label incorporated therein for detection purposes. Such a label may be chosen from labels that are known to those of ordinary skill in the art. Such labels include, but are not limited to, fluorescent labels. In one particular aspect, the primer may have a fluorescent label incorporated therein. And in a particular aspect, such a label may include 2AP. A unique property of the amplification process disclosed herein is that 2AP incorporated in the oligonucleotide results in strong fluorescence emission upon formation of a structure such as a quadruplex, thus serving as a sensitive detection probe for binding of the target sequence and subsequent formation of the quadruplex.
[0056] Other fluorescent nucleotides that can be utilized for detection of the quadruplex conformation can include pteridine analogs: 3-methyl isoxanthopterin (3MI) (Ex348, Em431), 6-methylisoxanthopterin (6MI) (Ex340, Em430) and (4-amino-6-methyl-8-(2¢-deoxy-â-D-ribofuranosyl)-7(8H)-pteridone (6AMP) (Ex330, Em435). As mentioned above, certain optical changes are naturally associated with the transformation to the quadruplex conformation. As such, it is also possible that the tertiary substrate transformation (from hairpin to quadruplex) can be detected without the use of added fluorophores or labeling compounds.
[0057] Methods of detecting a target nucleic acid are disclosed herein. The methods include obtaining a sample that includes the target nucleic acid. As described above, an oligonucleotide is provided that includes a first nucleotide sequence comprising a quadruplex-forming sequence and a second nucleotide sequence operably linked to the first nucleotide sequence, the second nucleotide sequence being sufficiently complementary to the target sequence to hybridize therewith. In some aspects, the oligonucleotide forms a hairpin conformation by hybridizing a stem sequence of the second nucleotide to the quadruplex-forming sequence of the first nucleotide sequence. The methods further include binding the target sequence to the second nucleotide sequence. Binding the target sequence to the second nucleotide sequence can include first binding the target sequence to a toehold sequence that is operably linked to the stem sequence while the oligonucleotide is in the hairpin conformation, then binding the target sequence to the stem sequence while the quadruplex-forming sequence dissociates from the stem sequence. Dissociation of the quadruplex-forming sequence from the stem sequence induces the quadruplex-forming sequence to take a quadruplex conformation, which can be detected, for example, by changes in optically detectable properties. Thus, the presence of the target sequence induces a detectable confirmation change in the oligonucleotide. Detection of the confirmation change therefore confirms the presence of the target sequence in the original sample. The oligonucleotide can be induced to revert from the quadruplex conformation back to the hairpin conformation by heating the sample.
[0058] In some aspects of the method, the quadruplex conformation is stabilized using potassium ions. The potassium concentration can be from 0.1 milliMolar to 100 milliMolar or more. The potassium concentration of the assay can be optimized depending on the desired results. For example, higher concentrations of potassium will yield faster reaction rates, but may lead to greater leakage than lower potassium concentrations. In one aspect, leakage can be reduced or eliminated by keeping the potassium concentration at less than 10 milliMolar (for example, at less than 1 milliMolar, less than 2 milliMolar, less than 3 milliMolar, less than 4 milliMolar, less than 5 milliMolar, less than 6 milliMolar, less than 7 milliMolar, less than 8 milliMolar, less than 9 milliMolar, and less than 10 milliMolar). However, advantages such as faster reaction rates may make concentrations of 10 milliMolar or greater desirable in certain aspects (for example, 10 milliMolar or greater, 20 milliMolar or greater, 30 milliMolar or greater, 40 milliMolar or greater, 50 milliMolar or greater, 60 milliMolar or greater, 70 milliMolar or greater, 80 milliMolar or greater, 90 milliMolar or greater, and 100 milliMolar or greater). In some aspect, the substrate is first dissolved in buffer comprising cesium and/or magnesium ions prior to the addition of the potassium ions.
[0059] In some aspects, the oligonucleotide in the quadruplex conformation is detected by registering a change in an optically detectable property. For example, changes in UV absorption or fluorescence emission can be measured and correlated to the presence of the quadruplex conformation. Specifically, upon binding of the target molecules to the hairpin, the quadruplex-forming sequence containing 2AP is released. The 2AP sequence is initially quenched by neighboring guanines in the hairpin. However, once the quadruplex forms, 2AP emits light and the fluorescence can be used to detect, and even quantify, the initial target molecules.
[0060] Interestingly, this method can be performed without the enzymes conventionally required for detecting and amplifying a nucleic acid signal. The ability to perform the assay without enzymes reduces cost and enables point of care diagnostics, which can be useful in many scenarios, one of which is in-field diagnostics, or diagnosis of subjects in locations where highly technical medical machinery is unavailable. In addition, non-enzymatic assays have greater stability and a longer shelf life at room temperature than enzymatic assays because they are based on oligonucleotides, which are more stable than enzymes.
[0061] The methods and oligonucleotides discussed above can be used to diagnose a subject with a disease or disorder. The methods include obtaining a bodily sample from the subject, extracting nucleic acids from the bodily sample, and contacting the nucleic acids from the bodily sample with the oligonucleotides discussed above. If the target nucleic acid is present within the nucleic acids from the bodily sample, they will bind to the second nucleotide sequence of the oligonucleotide, thereby inducing the oligonucleotide to take a quadruplex conformation. The quadruplex conformation can then be correlated with a diagnosis of the disease or disorder, a prognosis of the disease or disorder, or the development of the disease or disorder. The target nucleic acid sequence might be derived from any pathogen that causes the disease or disorder, including, but not limited to, malaria or tuberculosis. Alternatively, the target nucleic acid might be derived from the subject, and the methods can be used to detect genetic abnormalities or mutations that can lead to a disease or disorder. Likewise, the methods can be used to make a prognosis of a known disease or disorder, or to predict the development of a future disease or disorder.
Example 1
Introduction
[0062] Due to remarkable self-assembly properties, nucleic acids have been established as a favorable material for both static and dynamic nanotechnologies (1, 2). One of the main components of dynamic nanotechnologies is the driving force that allows unidirectional operations in an isolated system (i.e., irreversible transform of substrates into products or transport of an object from point A to point B without external stimuli) (3-6). Depending on the energy requirement, the DNA nanomachines can be divided into two major categories: technologies that employ enzymes (i.e., Ribozymes, DNAzymes or proteinous enzymes) to modify covalent bonds; and non-enzymatic technologies in which no covalent bonds are modified (1). The enzymatic technologies usually are based on cleavage of intermediate complexes. This allows spontaneous dissociation of the substrate and next round of activity in a steady-state, linear manner. Since in non-enzymatic assays no covalent bonds are modified, product can be used in the various downstream applications, i.e., cascading (6), or can serve as autocatalyst to accelerate reactions (4). Therefore, the non-enzymatic technologies are more versatile and induce strong interest due to their practical applications (i.e., point-of-care diagnostics) (7).
[0063] Dynamic nanotechnologies (i.e., gates, signal amplifiers, locomotives) are based on rearrangements between DNA duplexes. To make the reactions unidirectional, duplexed substrates are designed to be thermodynamically less favorable than their respective product duplexes (4, 6). As a result, the reactions are thermodynamically (enthalpically or entropically based on a system) driven, but demonstrate detrimental background-activity, or leakage (observed product formation before the addition of catalyst). To better understand the mechanism and challenges of reactions based on DNA-to-DNA transitions, consider an enthalpy-driven reaction. Reaction components for an enthalpy-driven reaction are shown in
[0064] In conclusion, both enthalpically and entropically driven reactions are governed by the same toehold activation/inactivation cycles. Specifically, before triggering the reactions, the catalyst toehold (dark grey) is exposed and active, while the fuel toehold (light grey) is inactivated by constraining into the substrates. The first strand-exchange event is accompanied by activation of the fuel toehold and simultaneous inactivation of the catalyst toehold. The second, and final, strand-exchange event constrains the fuel strand but exposes catalyst toehold in the product molecules, which can initiate undesired reverse reaction. However, the catalyst switches to the next substrate due to thermodynamic favorability of the product over the substrate (or incapability to invade the product). So, at the end of the cycle, the driving force of the reaction inactivates the exposed toehold and blocks the reverse reaction. In other words, the main role of the driving force is to ensure unidirectional nature of the reaction by inactivating the exposed toehold of the product.
[0065] Can the reverse reactions be blocked differently? For instance, by designing a reaction based on structural transformation (ST) between a DNA duplex and some highly packed non-canonical structure. This approach has already been used to transform thermocycling PCR (Polymerase Chain Reaction) into isothermal QPA (Quadruplex Priming Amplification) (8). The assay is based on GGGNGGGNGGGNGGG (SEQ ID NO: 5) (G3N) sequence, where N=G, A, C or T. G3N forms highly structured and unusually stable quadruplex.
[0066] This Example describes a non-enzymatically conducted ST reaction between a monomolecular DNA substrate and a quadruplex product (
[0067] As noted above, the approach is based on tertiary structure transformation (ST) between a DNA duplex (hairpin) and a quadruplex (
[0068]
[0069] In an example of the ST reaction, shown in
Materials and Methods:
[0070] DNA oligonucleotides were obtained from Integrated DNA Technologies (Coralville, Iowa). The quadruplex-forming sequence 5, shown in
[0071] UV absorption was recorded at 260 and 295 nm as a function of temperature using a Varian UV-visible spectrophotometer (Cary 100 Bio). Fluorescence measurements of 2AP (excitation 310 nm, emission 370 nm) were performed using a Varian spectrophotometer (Cary Eclipse). The devices were equipped with thermoelectrically-controlled cuvette holders. In a typical experiment, oligonucleotide stock solutions (usually 100 μM) were mixed into the desired buffers in optical cuvettes. The oligonucleotide solutions (4 μM in UV and 2 μM in fluorescence experiments) were incubated at 95° C. for a few minutes and annealed at room temperature for 2-3 minutes prior to ramping to the desired starting temperatures. In the case of the ST substrate (hairpin), to ensure that the quadruplex-forming sequence incorporated within the hairpin, the solutions were first annealed in CsCl- and MgCl.sub.2-containing buffers, and KCl was added after temperature annealing and ramping. The melting curves allowed an estimate of melting temperature, T.sub.m, the midpoint temperature of the unfolding process. To be sure that ST substrate forms only monomolecular structure, shown in
Results and Discussion
[0072] Melting profiles of ST substrate (Tuning ΔG.sub.Quadr to ΔG.sub.Hairpin):
[0073] The vertical lines marked 17 in
TABLE-US-00001 TABLE 1 Melting temperatures, T.sub.m, Van′t Hoff enthalpies, ΔH.sub.vH, and Gibbs free energies at 37° C., ΔG, for G3N quadruplex, 5′-GGGCGGGCGGG(2AP)GGG-3′ (SEQ ID NO: 1), and for TST substrate. G3N quadruplex TST substrate (hairpin) ΔH.sub.vH = −58 kcal/mol ΔH.sub.vH = −65 kcal/mol [K.sup.+] (mM)* T.sub.m(° C.) ΔG (kcal/mol) T.sub.m(° C.) ΔG (kcal/mol) 0 — — 83.0 −8.4 2 71.8 −5.9 83.0 −8.4 5 79.7 −7.0 82.4 −8.3 10 82.0 −7.5 ~80 −8 30 ~90 −9 ~68 −6 50 >95 <−9 ~65 −5 *The column indicates concentration of K.sup.+ in the buffers, which contain total 50 mM monovalent cations (K.sup.+ + Cs.sup.+) and 2 mM Mg.sup.2+. For instance, 2 mM [K.sup.+] corresponds to 2 mM K.sup.+, 48 mM Cs.sup.+ and 2 mM Mg.sup.2+.
[0074] OD.sub.260 is sensitive to duplex formation, while OD.sub.295 and 2AP-fluorescence monitor the quadruplex formation (8, 14-16). Therefore, in the absence of K.sup.+ (
[0075] The visible effect of K.sup.+ ions on the melting curves starts at ≥10 mM K.sup.+. As expected, the strongest effects are observed at [K.sup.+]=50 mM (
[0076] In conclusion, a drastic change in the melting behaviour of the ST substrate takes place around 10 mM K.sup.+, where both structures, hairpin and quadruplex, melt at similar temperatures, ˜80° C. Below this point, [K.sup.+]<10 mM, the quadruplex is less favorable than the hairpin (ΔG.sub.Quadr>ΔG.sub.Hairpin) and has no visible effect on the equilibrium transitions. However, at [K.sup.+]≥10 mM, the quadruplex becomes more favorable (ΔG.sub.Quadr<ΔG.sub.Hairpin) and, as a result, the transitions are non-equilibrium and irreversible since the quadruplex can't be incorporated into hairpins upon cooling. Thus, at [K.sup.+]≥10 mM the ST reactions is thermodynamically favorable (spontaneous), while at [K.sup.+]<10 mM it is thermodynamically unfavorable.
[0077] G3N quadruplex can't be invaded by a complement even under favorable conditions for the invasion: The previous section demonstrates that when formation of G3N quadruplex is more favorable than the hairpin the complementary segment of ST substrate is not able to invade already folded quadruplex. This is in general agreement with earlier observations that, at physiological conditions, invasion of the monomolecular quadruplexes with the complementary strands is unfeasible (17).
[0078] Here, we demonstrate that invasion of G3N quadruplex is problematic even under experimental conditions favorable for the invasion (when final duplex is more favorable than the quadruplex). For this, we studied invasion of 5′-GGGCGGGCGGG(2AP)GGG-3′ (SEQ ID NO: 1) quadruplex with its fully complementary DNA strand, 5′-CCCTCCCGCCCGCCC-3′ (SEQ ID NO: 6). The experiments were conducted in 0.1 mM K.sup.+ buffer (0.1 mM KCl, 50 mM CsCl and 2 mM MgCl.sub.2). Under this condition G3N quadruplex melts at ˜45° C. with favorable ΔH=−55 kcal/mol, (ΔG=−4 kcal/mol, estimated at 20° C.) while the duplex demonstrates T. of ˜72° C. with ΔH=−120 kcal/mol (ΔG=−18 kcal/mol). Thus, the duplex formation is drastically more favorable than the quadruplex.
[0079] Thus, when G3N sequence is securely trapped into the quadruplex (achieved at temperatures ˜20° C. below T.sub.m of the quadruplex), the complementary strand is incapable to invade even when the invasion is thermodynamically favorable. Without being wed to theory, this may be attributed to the highly compacted nature of G3N quadruplex employing only single-nt loops that are incapable to serve as toeholds to initiate invasion.
[0080] Self ST activity: As shown above, at [K.sup.+]≥10 mM the product is more favorable than the substrate and, as a result, the ST reaction has a thermodynamic driving force. However, at [K.sup.+]<10 mM the substrate is more favorable than the product and the reaction doesn't have a driving force. Since the main reason for the leakage for is a thermodynamic driving force, leakage in ST system is expected only at [K.sup.+]≥10 mM. Indeed, the fluorescence kinetics of ST substrate in the absence of the catalyst/target reveals measurable self-activity at [K.sup.+]=10 mM and 30 mM above 52° C., while no leakage is observed at [K.sup.+]=2 mM and 5 mM (
[0081] ST activity—Single turnover kinetics: Initially, single turnover reaction was tested using different targets, which demonstrated that 11-nt target, 5′-CTGGAAGCGGG-3′ (SEQ ID NO: 3) (T1) and 10-nt target, 5′-TGGAAGCGGG-3′ (SEQ ID NO: 4) (T2), (5-nt toehold+5-nt invasion) demonstrate fastest kinetics (
[0082] ST activity—Multiple turnover conditions (steady state kinetics):
[0083] Unless defined otherwise, all technical and scientific terms used herein have the same meanings as commonly understood by one of skill in the art to which the disclosed invention belongs.
[0084] Throughout this application, various publications and patent applications are referenced. The disclosures of these publications in their entireties are hereby incorporated by reference into this application in order to more fully describe the state of the art to which this disclosure pertains. However, it should be appreciated that any patent, publication, or other disclosure material, in whole or in part, that is said to be incorporated by reference herein is incorporated herein only to the extent that the incorporated material does not conflict with existing definitions, statements, or other disclosure material set forth in this disclosure. As such, and to the extent necessary, the disclosure as explicitly set forth herein supersedes any conflicting material incorporated herein by reference. Any material, or portion thereof, that is said to be incorporated by reference herein, but which conflicts with existing definitions, statements, or other disclosure material set forth herein will only be incorporated to the extent that no conflict arises between that incorporated material and the existing disclosure material.
[0085] Those skilled in the art will recognize, or be able to ascertain using no more than routine experimentation, many equivalents to the specific aspects of the invention described herein. While the invention has been described with reference to particular aspects and implementations, it will understood that various changes and additional variations may be made and equivalents may be substituted for elements thereof without departing from the scope of the invention or the inventive concept thereof. In addition, many modifications may be made to adapt a particular situation or device to the teachings of the invention without departing from the essential scope thereof. Such equivalents are intended to be encompassed by the following claims. It is intended that the invention not be limited to the particular implementations disclosed herein, but that the invention will include all implementations falling within the scope of the appended claims.
[0086] The corresponding structures, materials, acts, and equivalents of all means or step plus function elements in the claims below are intended to include any structure, material, or act for performing the function in combination with other claimed elements as specifically claimed. The description of the present invention has been presented for purposes of illustration and description, but is not intended to be exhaustive or limited to the invention in the form disclosed. Many modifications and variations will be apparent to those of ordinary skill in the art without departing from the scope and spirit of the invention. The implementation was chosen and described in order to best explain the principles of the invention and the practical application, and to enable others of ordinary skill in the art to understand the invention for various implementations with various modifications as are suited to the particular use contemplated.
TABLE-US-00002 SEQUENCES SEQ ID NO: 1 GGGCGGGCGGG(2AP)GGG SEQ ID NO: 2 CCCGC SEQ ID NO: 3 CTGGAAGCGGG SEQ ID NO: 4 TGGAAGCGGG SEQ ID NO: 5 GGGNGGGNGGGNGGG SEQ ID NO: 6 CCCTCCCGCCCGCCC SEQ ID NO: 7 GGGCGGGCGGG(2AP)GGGCCCGCTTCCAG SEQ ID NO: 8 GGGTGGGTGGGTGGG SEQ ID NO: 9 GGCGAAGGTC SEQ ID NO: 10 GGCGAAGGT SEQ ID NO: 11 TTCCAG
REFERENCES
[0087] 1. DeLuca, M.; Shi, Z.; Castro, C. E.; Arya, G., Dynamic DNA nanotechnology: toward functional nanoscale devices. Nanoscale Horizons 2020, 5, 182-201. [0088] 2. Zhang, D. Y.; Seelig, G., Dynamic DNA nanotechnology using strand-displacement reactions. Nat Chem 2011, 3 (2), 103-13. [0089] 3. Shin, J. S.; Pierce, N. A., A synthetic DNA walker for molecular transport. J Am Chem Soc 2004, 126 (35), 10834-5. [0090] 4. Yin, P.; Choi, H. M.; Calvert, C. R.; Pierce, N. A., Programming biomolecular self-assembly pathways. Nature 2008, 451 (7176), 318-22. [0091] 5. Yin, P.; Yan, H.; Daniell, X. G.; Turberfield, A. J.; Reif, J. H., A unidirectional DNA walker that moves autonomously along a track. Angew Chem Int Ed Engl 2004, 43 (37), 4906-11. [0092] 6. Zhang, D. Y.; Turberfield, A. J.; Yurke, B.; Winfree, E., Engineering entropy-driven reactions and networks catalyzed by DNA. Science 2007, 318 (5853), 1121-5. [0093] 7. Chen, X.; Briggs, N.; McLain, J. R.; Ellington, A. D., Stacking nonenzymatic circuits for high signal gain. Proc Natl Acad Sci USA 2013, 110 (14), 5386-91. [0094] 8. Kankia, B. I., Self-dissociative primers for nucleic acid amplification and detection based on DNA quadruplexes with intrinsic fluorescence. Anal Biochem 2011, 409 (1), 59-65. [0095] 9. Gogichaishvili, S.; Johnson, J.; Gvarjaladze, D.; Lomidze, L.; Kankia, B., Isothermal amplification of DNA using quadruplex primers with fluorescent pteridine base analogue 3-methyl isoxanthopterin. Biopolymers 2014, 101 (6), 583-90. [0096] 10. Taylor, A.; Joseph, A.; Okyere, R.; Gogichaishvili, S.; Musier-Forsyth, K.; Kankia, B., Isothermal quadruplex priming amplification for DNA-based diagnostics. Biophys Chem 2013, 171, 1-8. [0097] 11. Mathias, J.; Okyere, R.; Lomidze, L.; Gvarjaladze, D.; Musier-Forsyth, K.; Kankia, B., Thermal stability of quadruplex primers for highly versatile isothermal DNA amplification. Biophys Chem 2014, 185, 14-8. [0098] 12. Kankia, B. I.; Marky, L. A., DNA, RNA, and DNA/RNA oligomer duplexes: a comparative study of their stability, heat, hydration and Mg(2+) binding properties. J Phys Chem. B 1999, 103, 8759-8767. [0099] 13. Marky, L. A.; Breslauer, K. J., Calculating thermodynamic data for transitions of any molecularity from equilibrium melting curves. Biopolymers 1987, 26, 1601-1620. [0100] 14. Johnson, J.; Okyere, R.; Joseph, A.; Musier-Forsyth, K.; Kankia, B., Quadruplex formation as a molecular switch to turn on intrinsically fluorescent nucleotide analogs. Nucleic Acids Res 2013, 41 (1), 220-8. [0101] 15. Kankia, B. I.; Marky, L. A., Folding of the thrombin aptamer into a G-quadruplex with Sr(2+): stability, heat, and hydration. J Am Chem Soc 2001, 123 (44), 10799-804. [0102] 16. Mergny, J. L.; Phan, A. T.; Lacroix, L., Following G-quartet formation by UV-spectroscopy. FEBS Lett 1998, 435 (1), 74-8. [0103] 17. Oyaghire, S. N.; Cherubim, C. J.; Telmer, C. A.; Martinez, J. A.; Bruchez, M. P.; Armitage, B. A., RNA G-Quadruplex Invasion and Translation Inhibition by Antisense gamma-Peptide Nucleic Acid Oligomers. Biochemistry 2016, 55 (13), 1977-88.